A flow cytometric method for detection and enumeration of low‐level, residual red blood cells in platelets and mononuclear cell products

Abstract

This method for determining rRBCs in blood products is accurate and repeatable with a lower limit of detection adequate to assess currently available blood products. FC should be considered for determining rRBCs in MNC products.

Low frequency of anti‐D alloimmunization following D+ platelet transfusion: the Anti‐D Alloimmunization after D‐incompatible Platelet Transfusions (ADAPT) study

“…While the RBC content of each PC that was transfused during the study period was not quantified, quality control data from the participating centres indicated that the mean RBC content in PCs prepared from whole blood collections or obtained from apheresis devices was only 0·036 and 0·00043 ml, respectively (http://www.bancsang.net/en/professionals/resum_qualitat.html, last accessed 2 June 2014). These data, regarding the RBC content in PCs, are consistent with previous reports (Santana & Dumont, ; Culibrk et al , ). There is evidence that the minimum RBC volume necessary to elicit a primary anti‐D immune response is only 0·03 ml (Lozano & Cid, ), which is within the range of the quality control data from the centres in this study that transfused PCs prepared from whole blood collections.…”

Application of the ADVIA cerebrospinal fluid assay to count residual red blood cells in blood components

“…The level of residual red blood cells (rRBCs) in non‐RBC components for transfusion is of clinical interest due to potential morbidity related to ABO blood group mismatching and allo‐immunization to the Rh blood group antigen on RBCs [1]. In particular, high demand for platelet products and their short shelf life means that matching between platelet components and the recipient is not always possible.…”

Prospective surveillance of D− recipients of D+ apheresis platelets: alloimmunization against D is not detected

“…Since the earliest studies described above [6][7][8][9] the RBC contamination of apheresis PLTs, collected using modern equipment, has fallen from 3 mL per product 6 to less than 0.0027 mL per product. 12,14,[16][17][18] This is far below the 0.03-mL threshold generally believed to be the minimal RBC inoculum required for alloimmunization of healthy volunteers, 19 and suggests that modern apheresis products do not convey a risk of D alloimmunization. 15 In October 2012, in concert with this evolving literature, our medical center's transfusion committee authorized a change in policy whereby the offer of RhIG (300 μg) to adult recipients of D-incompatible apheresis PLT transfusions would be restricted to D− women of childbearing potential (age ≤50 years) who receive a transfusion of D+ PLTs.…”